UGH!!!!!! Google search result: On April 7,
Post# of 148279
Google search result:
On April 7, the Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy) for some patients with triple-negative breast cancer (TNBC). The agency's action follows last year's accelerated approval of the drug.May 12, 2021
I wish the Company gave us a heads up about this. It would have tempered expectations for gettting BTD for mTNBC.
At least we know to expect BTD for NASH, but its gonna be what....another 3-6 months assuming we submit for BTD within the next 2-4 weeks?